A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Multiple myeloma (MM) is the second most common adult hematologic malignancy in the western hemisphere, with an estimated 30,770 new cases and 12,770 expected deaths in 2018 [1]. While it remains an incurable cancer, survival outcomes of patients with MM have continued to increase particularly with the use of novel therapies, such as proteasome inhibitors (PI) and immunomodulatory drugs (IMID) [2], as well as treatment paradigms including upfront high-dose therapy/ autologous hematopoietic cell transplantation (HDT/AHCT) and post-transplant maintenance treatment [3].

Source: Biology of Blood and Marrow Transplantation - April 4, 2019 Category: Hematology Authors: Anita D'Souza, Parameswaran Hari, Marcelo Pasquini, Thomas Braun, Bryon Johnson, Steven Lundy, Daniel Couriel, Mehdi Hamadani, John Magenau, Binod Dhakal, Nirav N. Shah, Mary Riwes, Brian Parkin, Pavan Reddy, Attaphol Pawarode Source Type: research